Effect of Carbamazepine on the Pharmacokinetics (PK) of AT-527

• Status: Completed
• Trial end date: 2021-04-10
• Target enrollment: 0
• Participant gender: All

Summary

This study will determine the effect of carbamazepine on the PK of AT-527 (RO7496998) in healthy adult subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Atea Pharmaceuticals, Inc.
• Collaborator: Hoffmann-La Roche
• Treatments: Carbamazepine

Criteria

Inclusion Criteria:

• Must agree to use two methods of birth control from Screening through 90 days after administration of the last dose of study drug

• Females must have a negative pregnancy test at Screening and prior to dosing

• Minimum body weight of 50 kg and body mass index (BMI) of 18-29 kg/m2

• Willing to comply with the study requirements and to provide written informed consent

Exclusion Criteria:

• Pregnant or breastfeeding

• Infected with hepatitis B virus, hepatitis C virus, HIV or COVID-19

• Abuse of alcohol or drugs

• Use of other investigational drugs within 28 days of dosing

• Use of other prescription drugs with 28 days of dosing

• Other clinically significant medical conditions or laboratory abnormalities